Izotropic Valuation
Is 1R3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1R3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 1R3's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 1R3's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1R3?
Key metric: As 1R3 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 1R3's PB Ratio? | |
|---|---|
| PB Ratio | -0.7x |
| Book | -CA$4.28m |
| Market Cap | CA$2.84m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -2x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 1R3's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.7x | ||
AUG Audientes | 3.9x | n/a | €6.9m |
NN6 NanoRepro | 0.5x | n/a | €18.2m |
AAQ1 aap Implantate | 1.4x | n/a | €19.2m |
GME Geratherm Medical | 1x | 89.5% | €21.1m |
1R3 Izotropic | n/a | n/a | €2.8m |
Price-To-Book vs Peers: 1R3 has negative equity and a Price-To-Book Ratio (-0.7x) compared to the peer average (0.9x).
Price to Book Ratio vs Industry
How does 1R3's PB Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Book vs Industry: 1R3 has negative equity and a Price-To-Book Ratio (-0.7x) compared to the European Medical Equipment industry average (2.2x).
Price to Book Ratio vs Fair Ratio
What is 1R3's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -0.7x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 1R3's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.